Table of Content

1 Report Overview
1.1 Hepatic Encephalopathy Drugs Definition
1.2 Market by Type
1.2.1 Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Injection
1.2.3 Oral
1.3 Market Segment by Application
1.3.1 Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Hepatic Encephalopathy Drugs Sales
2.1 Global Hepatic Encephalopathy Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Hepatic Encephalopathy Drugs Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Hepatic Encephalopathy Drugs Revenue by Region
2.3.1 Global Hepatic Encephalopathy Drugs Revenue by Region (2018-2024)
2.3.2 Global Hepatic Encephalopathy Drugs Revenue by Region (2024-2034)
2.4 Global Hepatic Encephalopathy Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Hepatic Encephalopathy Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Hepatic Encephalopathy Drugs Sales Quantity by Region
2.6.1 Global Hepatic Encephalopathy Drugs Sales Quantity by Region (2018-2024)
2.6.2 Global Hepatic Encephalopathy Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Hepatic Encephalopathy Drugs Sales Quantity by Manufacturers
3.1.1 Global Hepatic Encephalopathy Drugs Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Hepatic Encephalopathy Drugs Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy Drugs Sales in 2022
3.2 Global Hepatic Encephalopathy Drugs Revenue by Manufacturers
3.2.1 Global Hepatic Encephalopathy Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Hepatic Encephalopathy Drugs Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy Drugs Revenue in 2022
3.3 Global Hepatic Encephalopathy Drugs Sales Price by Manufacturers
3.4 Global Key Players of Hepatic Encephalopathy Drugs, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Hepatic Encephalopathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Hepatic Encephalopathy Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Hepatic Encephalopathy Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Hepatic Encephalopathy Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Hepatic Encephalopathy Drugs Sales Quantity by Type
4.1.1 Global Hepatic Encephalopathy Drugs Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Hepatic Encephalopathy Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Hepatic Encephalopathy Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Hepatic Encephalopathy Drugs Revenue by Type
4.2.1 Global Hepatic Encephalopathy Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Hepatic Encephalopathy Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Hepatic Encephalopathy Drugs Price by Type
4.3.1 Global Hepatic Encephalopathy Drugs Price by Type (2018-2024)
4.3.2 Global Hepatic Encephalopathy Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Hepatic Encephalopathy Drugs Sales Quantity by Application
5.1.1 Global Hepatic Encephalopathy Drugs Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Hepatic Encephalopathy Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Hepatic Encephalopathy Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Hepatic Encephalopathy Drugs Revenue by Application
5.2.1 Global Hepatic Encephalopathy Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Hepatic Encephalopathy Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Hepatic Encephalopathy Drugs Price by Application
5.3.1 Global Hepatic Encephalopathy Drugs Price by Application (2018-2024)
5.3.2 Global Hepatic Encephalopathy Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Hepatic Encephalopathy Drugs Sales by Company
6.1.1 North America Hepatic Encephalopathy Drugs Revenue by Company (2018-2024)
6.1.2 North America Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024)
6.2 North America Hepatic Encephalopathy Drugs Market Size by Type
6.2.1 North America Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Hepatic Encephalopathy Drugs Revenue by Type (2018-2034)
6.3 North America Hepatic Encephalopathy Drugs Market Size by Application
6.3.1 North America Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Hepatic Encephalopathy Drugs Revenue by Application (2018-2034)
6.4 North America Hepatic Encephalopathy Drugs Market Size by Country
6.4.1 North America Hepatic Encephalopathy Drugs Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Hepatic Encephalopathy Drugs Revenue by Country (2018-2034)
6.4.3 North America Hepatic Encephalopathy Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Hepatic Encephalopathy Drugs Sales by Company
7.1.1 Europe Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024)
7.1.2 Europe Hepatic Encephalopathy Drugs Revenue by Company (2018-2024)
7.2 Europe Hepatic Encephalopathy Drugs Market Size by Type
7.2.1 Europe Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Hepatic Encephalopathy Drugs Revenue by Type (2018-2034)
7.3 Europe Hepatic Encephalopathy Drugs Market Size by Application
7.3.1 Europe Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Hepatic Encephalopathy Drugs Revenue by Application (2018-2034)
7.4 Europe Hepatic Encephalopathy Drugs Market Size by Country
7.4.1 Europe Hepatic Encephalopathy Drugs Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Hepatic Encephalopathy Drugs Revenue by Country (2018-2034)
7.4.3 Europe Hepatic Encephalopathy Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Hepatic Encephalopathy Drugs Sales by Company
8.1.1 China Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024)
8.1.2 China Hepatic Encephalopathy Drugs Revenue by Company (2018-2024)
8.2 China Hepatic Encephalopathy Drugs Market Size by Type
8.2.1 China Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Hepatic Encephalopathy Drugs Revenue by Type (2018-2034)
8.3 China Hepatic Encephalopathy Drugs Market Size by Application
8.3.1 China Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Hepatic Encephalopathy Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Hepatic Encephalopathy Drugs Sales by Company
9.1.1 APAC Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024)
9.1.2 APAC Hepatic Encephalopathy Drugs Revenue by Company (2018-2024)
9.2 APAC Hepatic Encephalopathy Drugs Market Size by Type
9.2.1 APAC Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Hepatic Encephalopathy Drugs Revenue by Type (2018-2034)
9.3 APAC Hepatic Encephalopathy Drugs Market Size by Application
9.3.1 APAC Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Hepatic Encephalopathy Drugs Revenue by Application (2018-2034)
9.4 APAC Hepatic Encephalopathy Drugs Market Size by Region
9.4.1 APAC Hepatic Encephalopathy Drugs Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Hepatic Encephalopathy Drugs Revenue by Region (2018-2034)
9.4.3 APAC Hepatic Encephalopathy Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 ASKA Pharmaceutical
11.1.1 ASKA Pharmaceutical Company Information
11.1.2 ASKA Pharmaceutical Overview
11.1.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Products and Services
11.1.5 ASKA Pharmaceutical Hepatic Encephalopathy Drugs SWOT Analysis
11.1.6 ASKA Pharmaceutical Recent Developments
11.2 Cosmo Pharmaceuticals
11.2.1 Cosmo Pharmaceuticals Company Information
11.2.2 Cosmo Pharmaceuticals Overview
11.2.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Products and Services
11.2.5 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs SWOT Analysis
11.2.6 Cosmo Pharmaceuticals Recent Developments
11.3 Bausch Health
11.3.1 Bausch Health Company Information
11.3.2 Bausch Health Overview
11.3.3 Bausch Health Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Bausch Health Hepatic Encephalopathy Drugs Products and Services
11.3.5 Bausch Health Hepatic Encephalopathy Drugs SWOT Analysis
11.3.6 Bausch Health Recent Developments
11.4 Ferring Pharmaceuticals
11.4.1 Ferring Pharmaceuticals Company Information
11.4.2 Ferring Pharmaceuticals Overview
11.4.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Products and Services
11.4.5 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs SWOT Analysis
11.4.6 Ferring Pharmaceuticals Recent Developments
11.5 Mallinckrodt
11.5.1 Mallinckrodt Company Information
11.5.2 Mallinckrodt Overview
11.5.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Mallinckrodt Hepatic Encephalopathy Drugs Products and Services
11.5.5 Mallinckrodt Hepatic Encephalopathy Drugs SWOT Analysis
11.5.6 Mallinckrodt Recent Developments
11.6 Umecrine Cognition
11.6.1 Umecrine Cognition Company Information
11.6.2 Umecrine Cognition Overview
11.6.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Umecrine Cognition Hepatic Encephalopathy Drugs Products and Services
11.6.5 Umecrine Cognition Hepatic Encephalopathy Drugs SWOT Analysis
11.6.6 Umecrine Cognition Recent Developments
11.7 Norgine
11.7.1 Norgine Company Information
11.7.2 Norgine Overview
11.7.3 Norgine Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Norgine Hepatic Encephalopathy Drugs Products and Services
11.7.5 Norgine Hepatic Encephalopathy Drugs SWOT Analysis
11.7.6 Norgine Recent Developments
11.8 Lupin
11.8.1 Lupin Company Information
11.8.2 Lupin Overview
11.8.3 Lupin Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Lupin Hepatic Encephalopathy Drugs Products and Services
11.8.5 Lupin Hepatic Encephalopathy Drugs SWOT Analysis
11.8.6 Lupin Recent Developments
11.9 Kaleido Biosciences
11.9.1 Kaleido Biosciences Company Information
11.9.2 Kaleido Biosciences Overview
11.9.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Products and Services
11.9.5 Kaleido Biosciences Hepatic Encephalopathy Drugs SWOT Analysis
11.9.6 Kaleido Biosciences Recent Developments
11.10 Kannalife Sciences
11.10.1 Kannalife Sciences Company Information
11.10.2 Kannalife Sciences Overview
11.10.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Kannalife Sciences Hepatic Encephalopathy Drugs Products and Services
11.10.5 Kannalife Sciences Hepatic Encephalopathy Drugs SWOT Analysis
11.10.6 Kannalife Sciences Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Hepatic Encephalopathy Drugs Value Chain Analysis
12.2 Hepatic Encephalopathy Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hepatic Encephalopathy Drugs Production Mode & Process
12.4 Hepatic Encephalopathy Drugs Sales and Marketing
12.4.1 Hepatic Encephalopathy Drugs Sales Channels
12.4.2 Hepatic Encephalopathy Drugs Distributors
12.5 Hepatic Encephalopathy Drugs Customers
13 Market Dynamics
13.1 Hepatic Encephalopathy Drugs Industry Trends
13.2 Hepatic Encephalopathy Drugs Market Drivers
13.3 Hepatic Encephalopathy Drugs Market Challenges
13.4 Hepatic Encephalopathy Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Injection
Table 3. Major Manufacturers of Oral
Table 4. Global Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Hepatic Encephalopathy Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Hepatic Encephalopathy Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2018-2024)
Table 8. Global Hepatic Encephalopathy Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2024-2034)
Table 10. Global Hepatic Encephalopathy Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034 (MT)
Table 11. Global Hepatic Encephalopathy Drugs Sales by Region (2018-2024) & (MT)
Table 12. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2018-2024)
Table 13. Global Hepatic Encephalopathy Drugs Sales by Region (2024-2034) & (MT)
Table 14. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2024-2034)
Table 15. Global Hepatic Encephalopathy Drugs Sales Quantity by Manufacturers (2018-2024) & (MT)
Table 16. Global Hepatic Encephalopathy Drugs Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Hepatic Encephalopathy Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Hepatic Encephalopathy Drugs Revenue Share by Manufacturers (2018-2024)
Table 19. Global Hepatic Encephalopathy Drugs Price by Manufacturers 2018-2024 (USD/Kg)
Table 20. Global Key Players of Hepatic Encephalopathy Drugs, Industry Ranking, 2021 VS 2022
Table 21. Global Hepatic Encephalopathy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Hepatic Encephalopathy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy Drugs as of 2022)
Table 23. Global Key Manufacturers of Hepatic Encephalopathy Drugs, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Hepatic Encephalopathy Drugs, Product Offered and Application
Table 25. Global Key Manufacturers of Hepatic Encephalopathy Drugs, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 28. Global Hepatic Encephalopathy Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 29. Global Hepatic Encephalopathy Drugs Sales Quantity Share by Type (2018-2024)
Table 30. Global Hepatic Encephalopathy Drugs Sales Quantity Share by Type (2024-2034)
Table 31. Global Hepatic Encephalopathy Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Hepatic Encephalopathy Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Hepatic Encephalopathy Drugs Revenue Share by Type (2018-2024)
Table 34. Global Hepatic Encephalopathy Drugs Revenue Share by Type (2024-2034)
Table 35. Hepatic Encephalopathy Drugs Price by Type (2018-2024) & (USD/Kg)
Table 36. Global Hepatic Encephalopathy Drugs Price Forecast by Type (2024-2034) & (USD/Kg)
Table 37. Global Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 38. Global Hepatic Encephalopathy Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 39. Global Hepatic Encephalopathy Drugs Sales Quantity Share by Application (2018-2024)
Table 40. Global Hepatic Encephalopathy Drugs Sales Quantity Share by Application (2024-2034)
Table 41. Global Hepatic Encephalopathy Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Hepatic Encephalopathy Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Hepatic Encephalopathy Drugs Revenue Share by Application (2018-2024)
Table 44. Global Hepatic Encephalopathy Drugs Revenue Share by Application (2024-2034)
Table 45. Hepatic Encephalopathy Drugs Price by Application (2018-2024) & (USD/Kg)
Table 46. Global Hepatic Encephalopathy Drugs Price Forecast by Application (2024-2034) & (USD/Kg)
Table 47. North America Hepatic Encephalopathy Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 49. North America Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 50. North America Hepatic Encephalopathy Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 51. North America Hepatic Encephalopathy Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Hepatic Encephalopathy Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 54. North America Hepatic Encephalopathy Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 55. North America Hepatic Encephalopathy Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Hepatic Encephalopathy Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Hepatic Encephalopathy Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Hepatic Encephalopathy Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Hepatic Encephalopathy Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Hepatic Encephalopathy Drugs Sales Quantity by Country (2018-2024) & (MT)
Table 61. North America Hepatic Encephalopathy Drugs Sales Quantity by Country (2024-2034) & (MT)
Table 62. Europe Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 63. Europe Hepatic Encephalopathy Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 65. Europe Hepatic Encephalopathy Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 66. Europe Hepatic Encephalopathy Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Hepatic Encephalopathy Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 69. Europe Hepatic Encephalopathy Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 70. Europe Hepatic Encephalopathy Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Hepatic Encephalopathy Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Hepatic Encephalopathy Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Hepatic Encephalopathy Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Hepatic Encephalopathy Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Hepatic Encephalopathy Drugs Sales Quantity by Country (2018-2024) & (MT)
Table 76. Europe Hepatic Encephalopathy Drugs Sales Quantity by Country (2024-2034) & (MT)
Table 77. China Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 78. China Hepatic Encephalopathy Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 80. China Hepatic Encephalopathy Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 81. China Hepatic Encephalopathy Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Hepatic Encephalopathy Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 84. China Hepatic Encephalopathy Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 85. China Hepatic Encephalopathy Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Hepatic Encephalopathy Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 88. APAC Hepatic Encephalopathy Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 90. APAC Hepatic Encephalopathy Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 91. APAC Hepatic Encephalopathy Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Hepatic Encephalopathy Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 94. APAC Hepatic Encephalopathy Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 95. APAC Hepatic Encephalopathy Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Hepatic Encephalopathy Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Hepatic Encephalopathy Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Hepatic Encephalopathy Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Hepatic Encephalopathy Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Hepatic Encephalopathy Drugs Sales Quantity by Region (2018-2024) & (MT)
Table 101. APAC Hepatic Encephalopathy Drugs Sales Quantity by Region (2024-2034) & (MT)
Table 102. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Company (2018-2024) & (MT)
Table 103. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Type (2018-2024) & (MT)
Table 105. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Type (2024-2034) & (MT)
Table 106. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Application (2018-2024) & (MT)
Table 109. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Application (2024-2034) & (MT)
Table 110. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Country (2018-2024) & (MT)
Table 116. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity by Country (2024-2034) & (MT)
Table 117. ASKA Pharmaceutical Company Information
Table 118. ASKA Pharmaceutical Description and Overview
Table 119. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 120. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product and Services
Table 121. ASKA Pharmaceutical Hepatic Encephalopathy Drugs SWOT Analysis
Table 122. ASKA Pharmaceutical Recent Developments
Table 123. Cosmo Pharmaceuticals Company Information
Table 124. Cosmo Pharmaceuticals Description and Overview
Table 125. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 126. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product and Services
Table 127. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs SWOT Analysis
Table 128. Cosmo Pharmaceuticals Recent Developments
Table 129. Bausch Health Company Information
Table 130. Bausch Health Description and Overview
Table 131. Bausch Health Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 132. Bausch Health Hepatic Encephalopathy Drugs Product and Services
Table 133. Bausch Health Hepatic Encephalopathy Drugs SWOT Analysis
Table 134. Bausch Health Recent Developments
Table 135. Ferring Pharmaceuticals Company Information
Table 136. Ferring Pharmaceuticals Description and Overview
Table 137. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 138. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product and Services
Table 139. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs SWOT Analysis
Table 140. Ferring Pharmaceuticals Recent Developments
Table 141. Mallinckrodt Company Information
Table 142. Mallinckrodt Description and Overview
Table 143. Mallinckrodt Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 144. Mallinckrodt Hepatic Encephalopathy Drugs Product and Services
Table 145. Mallinckrodt Hepatic Encephalopathy Drugs SWOT Analysis
Table 146. Mallinckrodt Recent Developments
Table 147. Umecrine Cognition Company Information
Table 148. Umecrine Cognition Description and Overview
Table 149. Umecrine Cognition Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 150. Umecrine Cognition Hepatic Encephalopathy Drugs Product and Services
Table 151. Umecrine Cognition Hepatic Encephalopathy Drugs SWOT Analysis
Table 152. Umecrine Cognition Recent Developments
Table 153. Norgine Company Information
Table 154. Norgine Description and Overview
Table 155. Norgine Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 156. Norgine Hepatic Encephalopathy Drugs Product and Services
Table 157. Norgine Hepatic Encephalopathy Drugs SWOT Analysis
Table 158. Norgine Recent Developments
Table 159. Lupin Company Information
Table 160. Lupin Description and Overview
Table 161. Lupin Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 162. Lupin Hepatic Encephalopathy Drugs Product and Services
Table 163. Lupin Hepatic Encephalopathy Drugs SWOT Analysis
Table 164. Lupin Recent Developments
Table 165. Kaleido Biosciences Company Information
Table 166. Kaleido Biosciences Description and Overview
Table 167. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 168. Kaleido Biosciences Hepatic Encephalopathy Drugs Product and Services
Table 169. Kaleido Biosciences Hepatic Encephalopathy Drugs SWOT Analysis
Table 170. Kaleido Biosciences Recent Developments
Table 171. Kannalife Sciences Company Information
Table 172. Kannalife Sciences Description and Overview
Table 173. Kannalife Sciences Hepatic Encephalopathy Drugs Sales Quantity (MT), Revenue (US$ Million), Average Selling Price (ASP) (USD/Kg) and Gross Margin (2018-2024)
Table 174. Kannalife Sciences Hepatic Encephalopathy Drugs Product and Services
Table 175. Kannalife Sciences Hepatic Encephalopathy Drugs SWOT Analysis
Table 176. Kannalife Sciences Recent Developments
Table 177. Key Raw Materials Lists
Table 178. Raw Materials Key Suppliers Lists
Table 179. Hepatic Encephalopathy Drugs Distributors List
Table 180. Hepatic Encephalopathy Drugs Customers List
Table 181. Hepatic Encephalopathy Drugs Market Trends
Table 182. Hepatic Encephalopathy Drugs Market Drivers
Table 183. Hepatic Encephalopathy Drugs Market Challenges
Table 184. Hepatic Encephalopathy Drugs Market Restraints
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
List of Figures
Figure 1. Hepatic Encephalopathy Drugs Product Picture
Figure 2. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Hepatic Encephalopathy Drugs Market Share by Type in 2022 & 2034
Figure 4. Injection Product Picture
Figure 5. Oral Product Picture
Figure 6. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Hepatic Encephalopathy Drugs Market Share by Application in 2022 & 2034
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Hepatic Encephalopathy Drugs Report Years Considered
Figure 12. Global Hepatic Encephalopathy Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Hepatic Encephalopathy Drugs Revenue 2018-2034 (US$ Million)
Figure 14. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Hepatic Encephalopathy Drugs Sales Quantity 2018-2034 (MT)
Figure 16. Global Hepatic Encephalopathy Drugs Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Hepatic Encephalopathy Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Hepatic Encephalopathy Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 19. North America Hepatic Encephalopathy Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Hepatic Encephalopathy Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 21. Europe Hepatic Encephalopathy Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Hepatic Encephalopathy Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 23. China Hepatic Encephalopathy Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Hepatic Encephalopathy Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 25. APAC Hepatic Encephalopathy Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity YoY (2018-2034) & (MT)
Figure 27. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Hepatic Encephalopathy Drugs Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Hepatic Encephalopathy Drugs Revenue in 2022
Figure 30. Hepatic Encephalopathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Hepatic Encephalopathy Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2018-2034)
Figure 33. Global Hepatic Encephalopathy Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2018-2034)
Figure 35. North America Hepatic Encephalopathy Drugs Revenue Market Share by Company in 2022
Figure 36. North America Hepatic Encephalopathy Drugs Sales Quantity Market Share by Company in 2022
Figure 37. North America Hepatic Encephalopathy Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Hepatic Encephalopathy Drugs Revenue Market Share by Type (2018-2034)
Figure 39. North America Hepatic Encephalopathy Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Hepatic Encephalopathy Drugs Revenue Market Share by Application (2018-2034)
Figure 41. North America Hepatic Encephalopathy Drugs Revenue Share by Country (2018-2034)
Figure 42. North America Hepatic Encephalopathy Drugs Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Hepatic Encephalopathy Drugs Sales Quantity Market Share by Company in 2022
Figure 46. Europe Hepatic Encephalopathy Drugs Revenue Market Share by Company in 2022
Figure 47. Europe Hepatic Encephalopathy Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Hepatic Encephalopathy Drugs Revenue Market Share by Type (2018-2034)
Figure 49. Europe Hepatic Encephalopathy Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Hepatic Encephalopathy Drugs Revenue Market Share by Application (2018-2034)
Figure 51. Europe Hepatic Encephalopathy Drugs Revenue Share by Country (2018-2034)
Figure 52. Europe Hepatic Encephalopathy Drugs Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 54. France Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. China Hepatic Encephalopathy Drugs Sales Quantity Market Share by Company in 2022
Figure 59. China Hepatic Encephalopathy Drugs Revenue Market Share by Company in 2022
Figure 60. China Hepatic Encephalopathy Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Hepatic Encephalopathy Drugs Revenue Market Share by Type (2018-2034)
Figure 62. China Hepatic Encephalopathy Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Hepatic Encephalopathy Drugs Revenue Market Share by Application (2018-2034)
Figure 64. APAC Hepatic Encephalopathy Drugs Sales Quantity Market Share by Company in 2022
Figure 65. APAC Hepatic Encephalopathy Drugs Revenue Market Share by Company in 2022
Figure 66. APAC Hepatic Encephalopathy Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Hepatic Encephalopathy Drugs Revenue Market Share by Type (2018-2034)
Figure 68. APAC Hepatic Encephalopathy Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Hepatic Encephalopathy Drugs Revenue Market Share by Application (2018-2034)
Figure 70. APAC Hepatic Encephalopathy Drugs Revenue Share by Region (2018-2034)
Figure 71. APAC Hepatic Encephalopathy Drugs Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 76. India Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Hepatic Encephalopathy Drugs Revenue Share by Country (2018-2034)
Figure 85. Brazil Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Hepatic Encephalopathy Drugs Revenue (2018-2034) & (US$ Million)
Figure 90. Hepatic Encephalopathy Drugs Value Chain
Figure 91. Hepatic Encephalopathy Drugs Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed